Cline Scientific, NecstGen Ink Manufacturing Agreement

Cline Scientific, a Swedish life science company developing a novel regenerative medicine, and NecstGen, a CDMO and center of excellence for cell and gene therapy, have signed a letter of intent to develop and manufacture clinical batches of Cline’s cell therapy for cartilage repair, StemCART.

Under terms of the partnership, NecstGen will support the further development and manufacture of Cline’s cell therapy for damaged cartilage, StemCART. StemCART is an Advanced Therapy Medicinal Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide. The Swedish therapy developer envisions to out-license StemCART to a commercial partner following successful in-human trial results.

Hanne Evenbratt, CEO of Cline Scientific said, “This LOI is an important first step in Cline’s preparation for the clinical phases of StemCART and a principal component of the manufacturing strategy. We are very excited to move forward with the team at NecstGen and anticipate a prosperous collaboration.”

Paul Bilars, CEO of NecstGen said, “We are happy to support Cline Scientific throughout this critical phase in the development of its StemCART therapy. This potential joint action is very much a demonstration of our mission to support organizations developing therapies for patients.”